N/A
N=5,946
Engaging Patients to Promote Deprescribing
Medical Overuse · Inappropriate Prescribing · Deprescriptions
Bottom Line
View on ClinicalTrials.gov: NCT04294901 ↗Enrolled (actual)
5,946
Serious AEs
1.0%
Results posted
May 2025
Primary outcome: Primary: Deprescribing — 748; 653 Participants — p=0.008
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Direct to patient medication brochure (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Deprescribing |
748; 653 | 0.008 sig |
| SECONDARY Deprescribing Conversations |
12; 37; 353 | — |
Summary
One mechanism to reduce potentially inappropriate medications is through deprescribing, a deimplementation-based approach to thoughtfully discontinue a medication a patient is currently prescribed. Many interventions to overcome deprescribing barriers target the provider, who is already overburdened. Although some believe providers have primary responsibility for deprescribing, patient-initiated discontinuation discussions can effectively facilitate deprescribing. In a single-site pilot study, the investigators successfully engaged VA Primary Care patients to facilitate deprescribing of select potentially inappropriate medications. The investigators now propose a multisite randomized controlled trial of engaging Veterans who may be deprescribing candidates. By study end, the investigators will have established the effectiveness of an innovative, low-tech, patient-focused intervention to promote deprescribing, thereby directly improving quality, safety, and value of VA care while also setting the stage for generalization of this approach to other potentially inappropriate medications.
Eligibility Criteria
Inclusion Criteria
- Veteran with a Primary Care appointment at one of three Veteran Affairs Medical Centers (including Community Based Outpatient Clinics)
- PPI Cohort:
- >90 consecutive days of PPI at any dose
- Diabetes Cohorts:
- HbA1c 65 years
- Renal impairment
- Cognitive impairment
- either >90 consecutive days insulin or sulfonylurea or >90 consecutive days of >2 DM medications (neither of which is insulin or sulfonylurea)
- Gaba Cohort:
- >90 consecutive days with total daily dose >1800mg
Exclusion Criteria
- PPI Cohort Exclusions:
- Diagnosis warranting PPI treatment
- Medication warranting PPI treatment
- Gaba Cohort Exclusions:
- Neuropathic pain
- Seizure disorder
- and/or Cancer-related pain
Data sourced from ClinicalTrials.gov (NCT04294901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.